Search clinical trials for: Integrase inhibitor

Total 65178 results

Boehringer Ingelheim

Completed

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

Healthy
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Dolutegravir Renal Impairment Study

Infection, Human Immunodeficiency Virus

United States
The Aurum Institute NPC
Johns Hopkins University

Recruiting

Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) (DOLPHIN KIDS)

HIV | Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

HIV Infections

United States
ViiV Healthcare

Completed

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

HIV Infections | Infection, Human Immunodeficiency Virus

Russian Federation
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

HIV Infections

United States
Centre Hospitalier Intercommunal de Toulon La Seyne...
Merck Sharp & Dohme LLC; Abbott

Completed

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (IntensVIH)

HIV Infections

France
Midway Specialty Care Center

Recruiting

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Hiv

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants

HIV Infections

United States, South Africa, Brazil, Tanzania, Thailand
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC

Completed

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients (LIVERAL)

Liver Failure | HIV Infection | Evidence of Liver Transplantation

France
Angela Kashuba, PharmD
Merck Sharp & Dohme LLC

Completed

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers

Healthy Volunteer

United States
Cairo University

Not yet recruiting

Effect of Integrated Neuromuscular Inhibition Technique in Females With Menstrual Low Back Pain

Dysmenorrhea
National Jewish Health
Merck Sharp & Dohme LLC

Completed

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

HIV

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Infection, Human Immunodeficiency Virus

United States
University of Nebraska

Completed

Measurement of Plasma and Intracellular Concentrations of Raltegravir

HIV

United States
Merck Sharp & Dohme LLC

Completed

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) (RACING)

HIV Infections
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis (LIVERAL)

Hepatitis C | Human Immunodeficiency Virus

Spain
ViiV Healthcare

Recruiting

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

HIV Infections

United States
Evandro Chagas National Institute of Infectious...
Beatriz Grinsztejn; Thiago Torres; Valdilea Gonçalves; Brenda Hoagland

Not yet recruiting

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir (ImPrepCab)

HIV Infections

Brazil
Chelsea and Westminster NHS Foundation Trust

Recruiting

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)

HIV-1-infection

United Kingdom
University of KwaZulu
Centre for the AIDS Programme of Research in South Africa

Recruiting

Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB (ORCHID)

Tuberculosis | Hiv

South Africa
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Infection, Human Immunodeficiency Virus

United States, France, Spain, Canada, Italy
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers

Weight Gain | Healthy Volunteer | Metabolic Effects | Integrase Strand Transfer Inhibitors

United States
Saint Michael's Medical Center
ViiV Healthcare

Active, not recruiting

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) (Sound)

Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

HIV-1 Infection

United States, Puerto Rico
Erasmus Medical Center
Catharina Ziekenhuis Eindhoven; Maasstad Hospital, Rotterdam; MC Haaglanden,... and other collaborators

Recruiting

Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study (DUALING)

Hiv

Netherlands
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Societa' Italiana Di Malattie Infettive E Tropicali

Recruiting

Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) (EDOLAS)

HIV-1-infection

Italy
Whitman-Walker Institute
ViiV Healthcare

Enrolling by invitation

Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care (CREATE)

HIV

United States
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (RALAM-II)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
Tibotec Pharmaceuticals, Ireland
Raltegravir is provided by Merck.

Completed

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

HIV Infections
Hospitales Universitarios Virgen del Rocío

Completed

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (RAET)

HIV Infections | HIV-1 Infection

Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Healthy

United States, Netherlands
Hospital Clinic of Barcelona

Completed

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients (RAL-LT-HIV)

Liver Transplantation | HIV Infections | Antiretroviral Therapy
University of Zurich

Unknown

Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection

Treatment Efficacy | Monotherapy | Dolutegravir | Primary HIV Infection

Switzerland
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

HIV Infection

United States
Canadian Immunodeficiency Research Collaborative
National Institutes of Health (NIH)

Completed

Integrase Inhibitor (MK-0518) Viral Decay

HIV Infections

Canada
Kristine Patterson, MD
Merck Sharp & Dohme LLC

Completed

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

HIV | AIDS

United States
The Affiliated Hospital of Qingdao University

Recruiting

Bioequivalence of Dotilavir Sodium Tablets in Healthy Subjects in the Fasting and Fed State

Healthy Volunteers

China
Asociacion para el Estudio de las Enfermedades...

Completed

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression (DOLBI)

HIV Infection

Spain
Merck Sharp & Dohme LLC

Approved for marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
University of Liverpool
Radboud University Medical Center; University of Cape Town; UNITAID; Liverpool... and other collaborators

Completed

Dolutegravir in Pregnant HIV Mothers and Their Neonates (DolPHIN-2)

Pregnancy Related | HIV-1-infection

Uganda, South Africa
University of Cape Town
Wellcome Trust; Médecins Sans Frontières, Belgium

Completed

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial (ARTIST)

HIV Infections

South Africa

3

Subscribe